InChIKey	VOVZXURTCKPRDQ-CQSZACIVSA-N
Canonical SMILES	O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	2
Pfam Stratification	Cross-Family
Avg pChEMBL	9.32
Source	ChEMBL;BindingDB

DrugBank ID	DB12597
Drug Name	Asciminib
CAS Number	1492952-76-7
Groups	approved investigational
ATC Codes	L01EA06
Description	Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML prolifer...

---

Categories: Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Inhibitors BCRP/ABCG2 Substrates Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2C19 inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Nicotinic Acids OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors OCT1 inhibitors P-glycoprotein inhibitors P-glycoprotein substrates Protein Kinase Inhibitors Pyridines Tyrosine Kinase Inhibitors UGT1A1 Inhibitors UGT2B17 substrates UGT2B7 substrates

---

Cross-references: BindingDB: 50459091 CHEMBL4208229 ChemSpider: 52085218 Drugs Product Database (DPD): 23749 PDB: AY7 PharmGKB: PA166268841 PubChem:72165228 PubChem:347828815 RxCUI: 2584304 Wikipedia: Asciminib ZINC: ZINC000150275965